Journal Options HIV - Volume 4, Issue 1
Course Directors: Joseph J. Eron, Jr., MD, William G. Powderly, MD, Andrew R. Zolopa, MD
View Collections |
|
|
|
Featured Expert Commentary
Richard D. Moore, MD, MHS
Professor, Medicine and Epidemiology
Director, Johns Hopkins HIV Clinic
Johns Hopkins University
Baltimore, Maryland
Volume 4, Issue 1 Articles
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1 and DUET-2: 24-week results from parallel randomised, double-blind, placebo-controlled trials.
Lazzarin A, Campbell T, Clotet B, et al. Lancet. 2007;370:39-48. Capsule Summary | Expert Commentary | Abstract | Slides
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1 and DUET-2: 24-week results from parallel randomised, double-blind, placebo-controlled trials.
Madruga JV, Cahn P, Grinsztejn B, et al. Lancet. 2007;370:29-38. Capsule Summary | Expert Commentary | Abstract | Slides
Safety and Efficacy of Darunavir (TMC114) With Low-Dose Ritonavir in Treatment-Experienced Patients: 24-Week Results of POWER 3.
Molina JM, Cohen C, Katlama C, et al. J Acquir Immune Defic Syndr. 2007;46:24-31. Capsule Summary | Expert Commentary | Abstract | Slides
Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.
Mocroft A, Phillips AN, Gatell J, et al. Lancet. 2007;370:407-413. Capsule Summary | Expert Commentary | Abstract | Slides
HIV-Infected Adults With a CD4 Cell Count Greater than 500 Cells/mm3 on Long-Term Combination antiretroviral Therapy Reach Same Mortality Rates as the General Population.
Lewden C, Chêne G, Morlat P, et al. J Acquir Immune Defic Syndr. 2007;46:72-77. Capsule Summary | Expert Commentary | Abstract | Slides
Response to Efavirenz-Containing Regimens in Previously Antiretroviral-Naive HIV-Positive Patients: The Role of Gender.
Smith CJ, Sabin CA, Youle MS, et al. J Acquir Immune Defic Syndr. 2007;46:62-67. Capsule Summary | Expert Commentary | Abstract | Slides
Ten-year predicted coronary heart disease risk in HIV-infected men and women.
Kaplan RC, Kingsley LA, Sharrett AR, et al. Clin Infect Dis. 2007;45:1074-1081. Capsule Summary | Expert Commentary | Abstract | Slides
Hepatotoxicity of Antiretroviral Drugs Is Reduced After Successful Treatment of Chronic Hepatitis C in HIV-Infected Patients.
Labarga P, Soriano V, Vispo ME, et al. J Infect Dis. 2007;196:670-676. Capsule Summary | Expert Commentary | Abstract | Slides
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
Madruga JV, Berger D, McMurchie M, et al. Lancet. 2007;370:49-58. Capsule Summary | Expert Commentary | Abstract | Slides
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
Volume 4, Issue 1
Collection
HIV Journal Options - Volume 4, Issue 1
Program Directors: Joseph J. Eron, Jr., MD, William G. Powderly, MD, Andrew R. Zolopa, MD
  
- Charles B. Hicks, MD
- Kenneth A. Lichtenstein, MD
- Mark S. Sulkowski, MD
|
  
- David M. Margolis, MD
- Joel E. Gallant, MD, MPH
- Richard D. Moore, MD, MHS
|
 
- Edwin DeJesus, MD, FACP, AAHIVS
- Kristine Patterson, MD
|
|